Study: Nearly 20 years on, no adverse impacts for pediatric cancer patients treated with dexrazoxan
A new study published in Cancer and authored by researchers at multiple institutions, including the University at Buffalo, demonstrates that dexrazoxane, which is administered to pediatric cancer patients in order to curb the cardiotoxicity of a key chemotherapy drug, has no adverse impacts on these patients, even nearly 20 years later.